{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:47:46Z","timestamp":1784940466925,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s11906-011-0200-4","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T03:07:33Z","timestamp":1301454453000},"page":"303-308","source":"Crossref","is-referenced-by-count":38,"title":["Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment"],"prefix":"10.1007","volume":"13","author":[{"given":"Guido","family":"Grassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Seravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Dell\u2019Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"200_CR1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","volume":"34","author":"G Mancia","year":"1999","unstructured":"Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724\u20138.","journal-title":"Hypertension"},{"key":"200_CR2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-007-9060-z","volume":"13","author":"JW Wright","year":"2008","unstructured":"Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev. 2008;13:367\u201375.","journal-title":"Heart Fail Rev"},{"key":"200_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1113\/expphysiol.2009.047381","volume":"95","author":"G Grassi","year":"2010","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F. The \u2018neuroadrenergic hypothesis\u2019 in hypertension: current evidence. Exp Physiol. 2010;95:581\u20136.","journal-title":"Exp Physiol"},{"key":"200_CR4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.84.5.2091","volume":"84","author":"MB Patel","year":"1991","unstructured":"Patel MB, Sterwart JM, Loud AV, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation. 1991;84:2091\u2013100.","journal-title":"Circulation"},{"key":"200_CR5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.HYP.0000141414.87026.4d","volume":"44","author":"W Briest","year":"2004","unstructured":"Briest W, Homagk L, Rassler B, et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension. 2004;44:410\u20138.","journal-title":"Hypertension"},{"key":"200_CR6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.109.142042","volume":"55","author":"SP Levick","year":"2010","unstructured":"Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension. 2010;55:270\u20136.","journal-title":"Hypertension"},{"key":"200_CR7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/01.HYP.0000185689.65045.4c","volume":"46","author":"S Perlini","year":"2005","unstructured":"Perlini S, Palladini G, Ferrero I, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension. 2005;46:1213\u20138.","journal-title":"Hypertension"},{"key":"200_CR8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.CIR.0000081775.72651.B6","volume":"108","author":"MP Schlaich","year":"2003","unstructured":"Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560\u20135.","journal-title":"Circulation"},{"key":"200_CR9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0735-1097(01)01600-X","volume":"38","author":"JP Greenwood","year":"2001","unstructured":"Greenwood JP, Scott EM, Stroker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"200_CR10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/CIRCULATIONAHA.106.668863","volume":"115","author":"J Burns","year":"2007","unstructured":"Burns J, Sivananthan MU, Ball SG, et al. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999\u20132005.","journal-title":"Circulation"},{"key":"200_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","volume":"53","author":"G Grassi","year":"2009","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baro-reflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205\u20139.","journal-title":"Hypertension"},{"key":"200_CR12","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1161\/01.CIR.92.11.3206","volume":"92","author":"G Grassi","year":"1995","unstructured":"Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206\u201311.","journal-title":"Circulation"},{"key":"200_CR13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/CS20000326","volume":"101","author":"G Grassi","year":"2001","unstructured":"Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex abnormalities in heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond). 2001;101:141\u20136.","journal-title":"Clin Sci (Lond)"},{"key":"200_CR14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/00004872-200409000-00019","volume":"22","author":"G Grassi","year":"2004","unstructured":"Grassi G, Seravalle G, Dell\u2019Oro R, et al. Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. J Hypertens. 2004;22:1747\u201353.","journal-title":"J Hypertens"},{"key":"200_CR15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/euhj.2000.2407","volume":"22","author":"HP Brunner-La Rocca","year":"2001","unstructured":"Brunner-La Rocca HP, Esler MD, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136\u201343.","journal-title":"Eur Heart J"},{"key":"200_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1365-201X.2003.01092.x","volume":"177","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Bertinieri G, Mancia G. Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. Acta Physiol Scand. 2003;177:399\u2013404.","journal-title":"Acta Physiol Scand"},{"key":"200_CR17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/01.HYP.0000098660.26184.63","volume":"42","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Quarti-Trevano F, et al. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873\u20137.","journal-title":"Hypertension"},{"key":"200_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009;54:690\u2013697. This review article examines data obtained in humans regarding the role of sympathetic neural factors in the development and progression of essential hypertension.","DOI":"10.1161\/HYPERTENSIONAHA.108.119883"},{"key":"200_CR19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/00004872-199917080-00011","volume":"17","author":"M Failla","year":"1999","unstructured":"Failla M, Grappiolo A, Emanuelli G, et al. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens. 1999;17:1117\u201323.","journal-title":"J Hypertens"},{"key":"200_CR20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.1991.71.3.659","volume":"71","author":"A Stella","year":"1991","unstructured":"Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71:659\u201382.","journal-title":"Physiol Rev"},{"key":"200_CR21","doi-asserted-by":"crossref","first-page":"R633","DOI":"10.1152\/ajpregu.00258.2005","volume":"289","author":"GF DiBona","year":"2005","unstructured":"DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633\u201341.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"200_CR22","doi-asserted-by":"crossref","unstructured":"\u2022 Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195\u20131201. This review highlights the potential of renal denervation as a procedure capable of lowering blood pressure in resistant hypertension.","DOI":"10.1161\/HYPERTENSIONAHA.109.138610"},{"key":"200_CR23","doi-asserted-by":"crossref","first-page":"R245","DOI":"10.1152\/ajpregu.00647.2009","volume":"298","author":"GF DiBona","year":"2010","unstructured":"DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245\u2013253.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"200_CR24","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1161\/01.CIR.0000034043.16664.96","volume":"106","author":"M Hausberg","year":"2002","unstructured":"Hausberg M, Kosch M, Harmalink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974\u20139.","journal-title":"Circulation"},{"key":"200_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011 Feb 7 (Epub ahead of print). This is the first report showing that adrenergic activation is detectable in the initial stages of renal failure.","DOI":"10.1161\/HYPERTENSIONAHA.110.164780"},{"key":"200_CR26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/hc1102.105261","volume":"105","author":"C Zoccali","year":"2002","unstructured":"Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354\u20139.","journal-title":"Circulation"},{"key":"200_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/HJH.0b013e3280119286","volume":"25","author":"M Hausberg","year":"2007","unstructured":"Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens. 2007;25:47\u20139.","journal-title":"J Hypertens"},{"key":"200_CR28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.ASN.0000106717.58091.F6","volume":"15","author":"F Mallamaci","year":"2004","unstructured":"Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15:435\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"200_CR29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.amjhyper.2005.02.002","volume":"18","author":"M Johansson","year":"2005","unstructured":"Johansson M, Gao SA, Friberg P, et al. Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens. 2005;18:995\u20131000.","journal-title":"Am J Hypertens"},{"key":"200_CR30","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al. 2007 Practice guidelines for the management of arterial hypertension: ESH-ESC task force for the management of arterial hypertension. J Hypertens. 2007;25:1751\u201362.","journal-title":"J Hypertens"},{"key":"200_CR31","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2174\/1381612043382756","volume":"10","author":"G Grassi","year":"2004","unstructured":"Grassi G. Sympathetic and baroreflex function in hypertension: implications for current and new drugs. Curr Pharm Design. 2004;10:3579\u201389.","journal-title":"Curr Pharm Design"},{"key":"200_CR32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/00004872-199816120-00012","volume":"16","author":"G Grassi","year":"1998","unstructured":"Grassi G, Turri C, Dell\u2019Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of circulation in essential hypertension. J Hypertens. 1998;16:1789\u201396.","journal-title":"J Hypertens"},{"key":"200_CR33","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","volume":"21","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Dell\u2019Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761\u20139.","journal-title":"J. Hypertens"},{"key":"200_CR34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.ASN.0000045049.72965.B7","volume":"14","author":"IH Klein","year":"2003","unstructured":"Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"200_CR35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004872-200405000-00007","volume":"22","author":"G Grassi","year":"2004","unstructured":"Grassi G. Neuroadrenergic effects of calcium channel blockers: a developing concept. J Hypertens. 2004;22:887\u20138.","journal-title":"J Hypertens"},{"key":"200_CR36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.HYP.0000058003.27729.5A","volume":"41","author":"G Grassi","year":"2003","unstructured":"Grassi G, Seravalle G, Turri C, et al. Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003;41:558\u201362.","journal-title":"Hypertension"},{"key":"200_CR37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00005344-200401000-00011","volume":"43","author":"Y Kitahara","year":"2004","unstructured":"Kitahara Y, Saito F, Akao M, et al. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol. 2004;43:68\u201373.","journal-title":"J Cardiovasc Pharmacol"},{"key":"200_CR38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2008-2660","volume":"94","author":"DV Menon","year":"2009","unstructured":"Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"200_CR39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","volume":"27","author":"PM Jansen","year":"2009","unstructured":"Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680\u201391.","journal-title":"J Hypertens"},{"key":"200_CR40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00004872-199917060-00001","volume":"17","author":"G Grassi","year":"1999","unstructured":"Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719\u201334.","journal-title":"J Hypertens"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-011-0200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-011-0200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-011-0200-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T14:25:18Z","timestamp":1560090318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-011-0200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s11906-011-0200-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}